Citations

Clear

14 citation(s) found for "Hu, Jianzhong".

Abstract 2496: In silico screening of therapeutics candidates targeting minimal residual disease in glioblastoma
Congivaram, Harrshavasan , Gomez, Mateo , McCortney, Katy, Wai, Ching Man , Zhang, Jianzhong, Brat, D. J., Horbinski, Craig M., Youngblood, Mark W., Ahrendsen, Jared T., Sonabend, Adam M., Magill, Stephen T., Tate, Matthew C., Lesniak, Maciej S., Sachdev, Sean, Sita, Timothy, Kumthekar, P., Buerki, Robin C., Primdahl, Ditte , Groot, John de, Reardon, David A., Lukas, Rimas V., Stupp, Roger, Heimberger, Amy B. , Tripathi, Shashwat , Du, Ruochen , Sears, Thomas , Brat, Daniel J. , Horbinski, Craig , Youngblood, Mark W. , Ahrendsen, Jared T. , Magill, Stephen T. , Tate, Matthew C. , Lesniak, Maciej S. , Sachdev, Sean , Sita, Timothy L., Dixit, Karan , Buerki, Robin, Khasraw, Mustafa , de Groot, John , Reardon, David A. , Lukas, Rimas V. , Stupp, Roger , Heimberger, Amy B.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2496-2496

10.1158/1538-7445.am2026-2496 Get It

Abstract Background: Glioblastoma recurrence is inevitable despite aggressive surgical resection of contrast enhancing (CE) tumor. Unlike the deep molecular characterization of CE glioblastoma, unresected infiltrating tumor, representing minimal residual disease (MRD) has not been well profiled. Increasingly, clinical trials are being conducted in the MRD setting for glioblastoma patients, necessitating understanding of unresected infiltrating tumor for targeted therapeutic development. Methods: Visium HD spatial transcriptomics was used to profile a cohort of newly diagnosed, treatment-naïve glioblastoma patients that underwent supramaximal resection, with both core and infiltrating in situ components. Spatial profiles generated expression signatures of infiltrative and CE tumor. For in silico prediction of therapeutics targeting the MRD, expression signatures of infiltrative and CE tumor were compared with drug perturbation signatures from the NIH L1000 database using the sRGES method to predict reversal of disease expression patterns. IC50 data from human cell lines were aggregated from the Genomics of Drug Sensitivity in Cancer or individual study data while blood-brain barrier (BBB) penetrance was predicted using the CNS-MPO approach. Findings: Infiltrative tumor expression profiles were enriched for genes corresponding to neural and oligodendrocyte progenitor like cells. In contrast CE glioblastoma displayed mesenchymal and astrocytic programs, suggesting spatial concentration of glioblastoma states within MRD and CE tumor. For CE glioblastoma, proteasome inhibitors and glucocorticoid receptor agonists were predicted to have the highest antitumor activity. In contrast, histone deacetylase inhibitors (HDACi) were highly ranked for MRD while exhibiting low predicted efficacy in CE tumor. Synergy analysis of drug candidates provided multiple dual treatment options for both the CE and MRD contexts. Conclusions: Cumulatively, these data indicate that the resected tumor does not reflect the MRD state, providing clarity on why targeted therapeutics for glioblastoma have not been particularly successful. Spatial profiling of the MRD demonstrates vulnerability to unique drug targets, which if utilized in the correct setting could confer greater survival benefit. Citation Format: Harrshavasan Congivaram, Shashwat Tripathi, Mateo Gomez, Katy McCortney, Ching Man Wai, Ruochen Du, Thomas K. Sears, Jianzhong Zhang, Daniel J. Brat, Craig M. Horbinski, Mark W. Youngblood, Jared T. Ahrendsen, Adam M. Sonabend, Stephen T. Magill, Matthew C. Tate, Maciej S. Lesniak, Sean Sachdev, Timothy Sita, Priya Kumthekar, Karan Dixit, Robin Buerki, Ditte Primdahl, Mustafa Khasraw, John de Groot, David A. Reardon, Rimas V. Lukas, Roger Stupp, Amy B. Heimberger. In silico screening of therapeutics candidates targeting minimal residual disease in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2496.
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer
Moding, Everett J. , Esfahani, Mohammad Shahrokh , Jin, Cheng , Hui, Angela B. , Nabet, Barzin Y. , Liu, Yufei , Chabon, Jacob J. , Binkley, Michael S. , Kurtz, David M. , Hamilton, Emily G. , Chaudhuri, Aadel A. , Liu, Chih Long , Bonilla, Rene F., Jiang, Alice L. , Lau, Brianna , Lopez, Pablo , He, Jianzhong, Qiao, Yawei, Yao, Luyang , Gandhi, Saumil , Das, Millie , Ramchandran, Kavitha , Padda, Sukhmani K. , Neal, Joel W. , Wakelee, Heather A. , Li, Ruijiang , Alizadeh, Ash A. , Shahrokh Esfahani, Mohammad , Li, Zhe , Bonilla, Rene F , Jiang, Alice L , Lau, Brianna C , Lopez, Pablo , He, Jianzhong , Qiao, Yawei , Xu, Ting , Yao, Luyang , Gandhi, Saumil , Liao, Zhongxing , Das, Millie , Ramchandran, Kavitha J , Padda, Sukhmani K , Neal, Joel W , Wakelee, Heather A , Gensheimer, Michael F , Loo, Billy W , Li, Ruijiang , Lin, Steven H , Alizadeh, Ash A , Diehn, Maximillian , Binkley, Michael Sargent , Kurtz, David M , Loo, Billy W. , Lin, Steven H. , Diehn, Maximilian

Mayo Clinic

Cancer Discovery | April 29, 2025 | Volume: 15 | Issue: 8 | Pages: 1609-1629

10.1158/2159-8290.cd-24-1704 | PMID 40299851 Get It

Abstract The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534
S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
Dubinsky, Marla C. , D’Haens, Geert , Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, Samuel I., Garrison, Andrew, Dewit, Olivier , Juillerat, Pascal , Panaccione, Remo , Fujii, Toshimitsu , Anyanwu, Samuel, Doshi, Chirag, Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0000954280.83972.54 Get It

S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results
Lacerda, Ana P. , D’Haens, Geert , Reinisch, Walter, Louis, Édouard , Chen, Minhu , Boland, Brigid S. , Dubcenco, Elena, Feng, Tian, Panés, Julián , Loftus, Edward V. , Peyrin‐Biroulet, Laurent , Panaccione, Remo , Reinisch, Walter , Louis, Edouard , Nakase, Hiroshi , Begun, Jakob , Liu, Jianzhong , Mohamed, Mohamed‐Eslam F. , Feng, Tian, Colombel, Jean‐Frédéric

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S10-S10

10.14309/01.ajg.0000897656.25080.34 Get It

Hospital hyperglycemia: Status Investigation and Effect of a Real-time Glycemic Alert System
Cao, Chenxiang , Bernet, Victor , Li, Caihong , Bi, Chongyang, Sang, Zhenhua , Xiao, Jianzhong , Liu, Zhaoxiang

Mayo Clinic

No container title available | January 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.160978549.91505716/v1 Get It

BACKGROUND Hospital hyperglycemia is common and associated with potential adverse outcomes. A Hospital-wide Mobile Phone Alert (HMA) system was built to achieve real time glucose monitoring with warnings for glucose excursions. This study investigated the status of glucose control and evaluated the impact of HMA system on inpatient glycemia management. METHODS Inpatients with hyperglycemia hospitalized between 1 January, 2017 and 31 December, 2018 were identified excluding those < 18 years of age. The HMA system was activated on 1 October, 2017. It sent real time cellphone warning messages to the patient’s designated team physician whenever glucose levels > 10 mmol/L or < 3 mmol/L were detected. A serum glucose > 7.8 mmol/L was defined as hospital hyperglycemia (HH), and > 10 mmol/L was defined as significant HH (SHH). Glucose excursions before and after the HMA system was instituted were compared. RESULTS The incidence of HH, SHH and hypoglycemia was 26.1%, 12.8% and 2.5%, respectively. With the HMA system, the monthly glucose related consultation rate for all inpatients increased 65.9%. The rate of HH glucose amount/ total glucose amount improved with the HMA system, being lower than pre HMA system activation for the surgical wards (15.8 ± 4.7% vs 21.1 ± 6.1%,p<0.05). CONCLUSIONS In this study, one third of inpatients were noted to experience hyperglycemia. Real time cellphone warning messages to the patient’s designated team physician can improve consultation utilization for blood glucose excursions. The alert system was found to reduce the incidence of hyperglycemia on surgical wards.
S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study
D’Haens, Geert , Louis, Édouard , Lacerda, Ana P. , Panés, Julián , Louis, Edouard , Zhou, Qian , Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S322-S323

10.14309/01.ajg.0000704620.03018.6c Get It

Hospital Hyperglycemia: Status Investigation and Effect of a Real-time Glycemic Alert System
Cao, Chenxiang , Bernet, Victor , Li, Caihong , Bi, Chongyang, Sang, Zhenhua , Liu, haiyi, Xiao, Jianzhong , Liu, Zhaoxiang

Mayo Clinic

No container title available | May 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159015070.08822242 Get It

OBJECTIVE Hospital hyperglycemia is common and associated with potential adverse outcomes. A Hospital-wide Mobile Phone Alert (HMA) system was built to achieve real time glucose monitoring with warnings for glucose excursions. This study investigated the status of glucose control and evaluated the impact of HMA system on inpatient glycemia management. METHODS Inpatients with hyperglycemia hospitalized between 1 January, 2017 and 31 December, 2018 were identified excluding those < 18 years of age. The HMA system was activated on 1 October, 2017. It sent real time cellphone warning messages to the patient’s designated team physician whenever glucose levels > 10 mmol/L or < 3 mmol/L were detected. A serum glucose > 7.8 mmol/L was defined as hospital hyperglycemia (HH), and > 10 mmol/L was defined as significant HH (SHH). Glucose excursions before and after the HMA system was instituted were compared. RESULTS The incidence of HH, SHH and hypoglycemia was 26.1%, 12.8% and 2.5%, respectively. With the HMA system, the monthly glucose related consultation rate for all inpatients increased 65.9%. The rate of HH glucose amount/ total glucose amount improved with the HMA system, being lower than pre HMA system activation for the surgical wards (15.8 ± 4.7% vs 21.1 ± 6.1%,p<0.05). CONCLUSIONS In this study, one third of inpatients were noted to experience hyperglycemia. Real time cellphone warning messages to the patient’s designated team physician can improve consultation utilization for blood glucose excursions. The alert system was found to reduce the incidence of hyperglycemia on surgical wards.
MON-LB120 MODY3 With Insulin Coding Gene Mutation and Craniofacial Microsomia: A Case Report
Cao, Chenxiang , Bernet, Victor , Xiao, Jianzhong , Han, Xueyao , Ma, Yumin

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.2136 Get It

Abstract Background: Maturity onset diabetes in young 3 (MODY 3) is caused by mutation of the hepatic nuclear factor 1 alpha (HNF-1A) gene. Craniofacial macrosomia (CFM) is associated with an abnormal development of craniofacial structures during the embryonic period. Maternal diabetes and genetic predisposition have been associated with CFM1. There are rare reports about an association of MODY 3 and CFM. Clinical case: An 11-year-old male patient presented with right side CFM (mild mandibular hypoplasia, internal auditory canal absence, severe pinna hypoplasia, abnormal orbital size and location, O3.M0.E3.N0.S02) noted at 8 months of age. Preoperative examination revealed A1c at 10.9%. After short term intensive insulin therapy, he had standard bread meal test: fasting glucose 8.11 mmol/L, insulin 13.9 mIU/L (3-25), C-peptide 1.25 ng/ml (0.81-3.85); 1 hour glucose 10.05 mmol/L, insulin 27 mIU/L, C-peptide 2.42 ng/ml; 2 hour glucose 8.17 mmol/L, insulin 16.09 mIU/L, C-peptide 2.11 ng/ml. GADA, IAA and ICA were negative. The mother was diagnosed diabetes at age 27years, when the patient was 8-month-old, and received insulin therapy. The mother was blind by age 35years due to diabetic retinopathy and died of DKA at 38-years-old. The patient’s 16-year-old brother had left side CFM (O2.M1.E2.N0.S0) and his OGTT was normal. The father was diagnosed with impaired glucose tolerance. The family had whole genome sequencing by Sanger technique, and resequenced the mutation with side primers. The CGA to CAA mutation was present at the 686 loci of exon 3 of HNF1A gene in the patient and mother. The HNF1A exon 3 mutation of CGA to CAA resulted in the change of arginine to glutamine which by the HGMA database is recognized as a reported MODY3 gene mutation. There was a mutation of G to A in the 4 loci of exon 1 of the insulin coding region in chromosome 11 in both the patient and elder brother. Neither elder brother nor father had the CGA mutation of HNF1A. Conclusion: There has not been a previous report of a relationship between HNF1A and CFM. In this case, the elder brother had CFM without a HNF1A mutation which does not support a connection between CFM and HNF1A. The two brothers both had CFM and insulin coding gene mutations which would represent a new association not previously described. Further testing is needed to confirm a relationship between the two. Reference: 1. Chen Q, Zhao Y, Shen G, Dai J. Etiology and Pathogenesis of Hemifacial Microsomia. J Dent Res 2018; 97(12): 1297-305. 2. Gougoutas AJ, Singh DJ, Low DW, Bartlett SP. Hemifacial microsomia: clinical features and pictographic representations of the OMENS classification system. Plast Reconstr Surg 2007; 120(7): 112e-20e.